aflibercept (Eylea)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

* see clinical trials below

Dosage

solution for injection

Mechanism of action

Clinical trials

More general terms

More specific terms

References

  1. FDA NEWS RELEASE: Nov. 18, 2011 FDA approves Eylea for eye disorder in older people http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm
  2. 2.0 2.1 The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692915 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
    Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692914 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1500351
  3. 3.0 3.1 FDA News Release. March 25, 2015 FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439838.htm
  4. 4.0 4.1 Maturi RK, Glassman AR, Josic K et al Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. JAMA. 2023;329(5):376-385 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36749332 https://jamanetwork.com/journals/jama/fullarticle/2801058
  5. aflibercept (Eylea) prescribing information http://www.regeneron.com/docs/eylea-fpi.pdf